摘要
目的:探讨"3+7"与地西他滨+HAG预激方案治疗高龄骨髓异常增生综合征继发AML患者的临床疗效及安全性差异。方法:选取我院2012年3月-2014年5月收治高龄骨髓异常增生综合征继发AML患者50例,随机分为A组(25例)和B组(25例),分别采用"3+7"与地西他滨+HAG预激方案治疗,比较两组患者临床疗效、骨髓抑制时间、毒副作用发生率、生活质量及生存情况。结果:B组患者临床总缓解率显著高于A组患者(P<0.05);B组患者化疗过程中外周血白细胞减少和粒细胞缺乏的天数及化疗后二者恢复的天数明显缩短(P<0.05);B组肺感染发生率明显低于A组(P<0.05),两组患者中其他药物毒副作用发生率比较差异无统计学意义(P>0.05);B组患者治疗后生活质量明显优于A组患者(P<0.05);B组患者平均生存时间和中位生存时间显著长于A组患者(P<0.05)。结论:地西他滨+HAG预激方案较传统"3+7"方案治疗高龄骨髓异常增生综合征继发AML可有效延缓患者病情进展,缩短骨髓抑制时间,降低肺感染发生率,同时延长生存时间。
Objective：To investigate the clinical efficacy and safety of ＂3 ＋ 7＂ regimen and decitabine ＋ HAG preexcitation regimen in the treatment of elderly MDS patients with AML transformed by abnormal proliferation of bone marrow.Methods：Fifty elderly patients with AML transformed by abnormal proliferation of bone marrow in the period from March 2012 to May 2014 were chosen and randomly divided into 2 groups including A group（25 elderly patients treated with ＂3 ＋ 7＂ regimen） and B group（25 elderly patients treated with decitabine ＋ HAG pre-excitation regimen）,and the clinical effeicacy,the median survival time and the incidence of drug adverse effects in 2 groups were compared.Results：The clinical total remission rate in B group was significantly higher than that in A group（P〈0.05）.The leukopenia time,neutropenia time and recovery time of leukocyte and neutrophilia in B group were significantly shorter than those in A group,the differences were statistically significant（P〈0.05）.The rate of lung infection in B group was significantly lower than that in A group.There was no significant difference in the incidence of other drug adverse effects between 2 groups（P 〉 0.05）.The life quality of patients in B group was significantly prior to patients in A group,and the difference was statistically significant（P〈0.05）.The average survival time and the median survival time of patients in B group was significantly longer than those in A group（P〈0.05）.Conclusion：Compared with ＂ 3 ＋7＂ regimen,the decitabine ＋ HAG pre-excitation regimen in the treatment of elderly patients with AML transformed by abnormal proliferation of bone marrow can efficiently delay the disease progression process,shorten the time of bone marrow suppression,decrease the rate of lung infection and prolong the survival time.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2016年第5期1484-1488,共5页
Journal of Experimental Hematology
